Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
4.16
Dollar change
-0.35
Percentage change
-7.76
%
Index- P/E- EPS (ttm)-1.93 Insider Own- Shs Outstand36.04M Perf Week3.74%
Market Cap136.66M Forward P/E- EPS next Y-2.29 Insider Trans- Shs Float- Perf Month-10.73%
Income-64.78M PEG- EPS next Q- Inst Own2.91% Short Float- Perf Quarter-5.88%
Sales9.43M P/S14.49 EPS this Y-155.66% Inst Trans-0.92% Short Ratio3.93 Perf Half Y-32.79%
Book/sh6.53 P/B0.64 EPS next Y-6.80% ROA-24.72% Short Interest0.06M Perf Year-39.18%
Cash/sh6.88 P/C0.61 EPS next 5Y- ROE-27.57% 52W Range3.53 - 7.32 Perf YTD-0.48%
Dividend Est.- P/FCF- EPS past 5Y- ROI-29.79% 52W High-43.17% Beta0.79
Dividend TTM- Quick Ratio14.58 Sales past 5Y452.58% Gross Margin- 52W Low17.85% ATR (14)0.29
Dividend Ex-Date- Current Ratio14.58 EPS Y/Y TTM-148.70% Oper. Margin-686.66% RSI (14)43.20 Volatility7.95% 4.62%
Employees191 Debt/Eq0.02 Sales Y/Y TTM-95.37% Profit Margin-686.96% Recom3.00 Target Price7.97
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q6.96% Payout0.00% Rel Volume0.21 Prev Close4.51
Sales Surprise- EPS Surprise- Sales Q/Q17.61% Earnings- Avg Volume15.40K Price4.16
SMA20-8.30% SMA50-7.41% SMA200-22.50% Trades Volume3,160 Change-7.76%
Date Action Analyst Rating Change Price Target Change
Aug-30-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-29-22Downgrade SVB Leerink Outperform → Mkt Perform $30 → $8
May-25-22Upgrade Credit Suisse Underperform → Neutral
Apr-27-22Downgrade Credit Suisse Neutral → Underperform
Jul-13-21Initiated Cowen Outperform $50
Jul-12-21Resumed SVB Leerink Outperform $36
Mar-01-24 04:00PM
Jan-07-24 04:00PM
Jan-05-24 04:00PM
Dec-14-23 01:00AM
Dec-10-23 12:00PM
01:00AM Loading…
Nov-14-23 01:00AM
Nov-03-23 12:00PM
Nov-02-23 02:00AM
Nov-01-23 02:00AM
Oct-26-23 04:00PM
Sep-13-23 01:00AM
Aug-24-23 04:00PM
Jul-13-23 08:06AM
Jun-27-23 01:00AM
Jun-19-23 12:00PM
08:59AM Loading…
Jun-02-23 08:59AM
May-25-23 05:01PM
May-16-23 04:00PM
May-13-23 02:00AM
May-11-23 04:00PM
Apr-18-23 01:44AM
Apr-14-23 01:00AM
Apr-04-23 11:44AM
Mar-13-23 09:30AM
12:22AM
Mar-11-23 02:14AM
Mar-09-23 04:00PM
Mar-02-23 04:00PM
Feb-28-23 01:15AM
Feb-10-23 01:00AM
01:00AM Loading…
Jan-16-23 01:00AM
Jan-12-23 06:18AM
Jan-08-23 03:00PM
Dec-30-22 01:00AM
Dec-12-22 07:00PM
Dec-01-22 11:46PM
Nov-10-22 01:00AM
Nov-04-22 09:39AM
Nov-03-22 12:30PM
Nov-02-22 12:30PM
Oct-27-22 04:00PM
04:00PM
Aug-25-22 04:30PM
Aug-18-22 01:00AM
Jul-21-22 11:30AM
Jun-10-22 01:00AM
May-12-22 04:05PM
May-11-22 01:00AM
May-03-22 12:00PM
Apr-27-22 08:02AM
06:01AM
05:59AM
Apr-26-22 04:05PM
02:00PM
Apr-23-22 01:00AM
Apr-13-22 12:00PM
09:00AM
Mar-24-22 02:00AM
Mar-17-22 01:00AM
Mar-15-22 04:30PM
Feb-25-22 04:30PM
Feb-11-22 04:10PM
Feb-10-22 07:13AM
01:00AM
Jan-28-22 05:57AM
Jan-23-22 02:28AM
Jan-18-22 01:00AM
Jan-13-22 05:00PM
Jan-12-22 10:13AM
Jan-11-22 11:37AM
Jan-10-22 06:51PM
09:32AM
08:58AM
07:31AM
07:13AM
05:46AM
03:35AM
01:17AM
Jan-06-22 10:00AM
Jan-05-22 04:05PM
Dec-15-21 01:00AM
Dec-14-21 12:16PM
01:00AM
Dec-12-21 04:00PM
Dec-09-21 01:00AM
Dec-06-21 01:00AM
Dec-03-21 01:00AM
Nov-30-21 12:48PM
01:00AM
Nov-24-21 01:00AM
Nov-16-21 06:49AM
05:51AM
01:00AM
Nov-04-21 02:00AM
Oct-28-21 01:00AM
Oct-20-21 01:00AM
Sep-03-21 04:05PM
Aug-26-21 01:00AM
Aug-09-21 01:00AM
Jul-13-21 06:55AM
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Pluckthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.